What is it about?
The detection of free Apo(a) by a ligand-immuno-assay allows a higher specificity and sensitivty in the detection of risk factors for CHD patients that the currently used test for the detection of Lp(a). Lp(a) is composed from ApoB-100 + Apo(a). The second component is bound at the ApoB at the same site as the LDL-Receptor binding site is placed at ApoB. By using the same binding site for free Apo(a), the in-vivo situation can be simulated.
Featured Image
Why is it important?
It's by design (Ligand-Immuno Assay) a test system which allows to simulate in-vivo conditions. Therefore we found a higher sensitivity and specificity for the test parameter fApo(a) than for Lp(a).
Perspectives
The use of assay which simulates the pathogenesis of a disease allows deeper insights into the processes running in vivo.
Dr Stephan T. Kiessig
VCC Medical Deutschland GmbH
Read the Original
This page is a summary of: Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease, Clinical Chemistry and Laboratory Medicine (CCLM), January 1999, De Gruyter,
DOI: 10.1515/cclm.1999.003.
You can read the full text:
Contributors
The following have contributed to this page
